Witold Prejzner
Overview
Explore the profile of Witold Prejzner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giordano U, Piekarska A, Prejzner W, Gil L, Zaucha J, Kujawska J, et al.
Biomedicines
. 2025 Jan;
13(1).
PMID: 39857747
: The implementation of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) has brought a significant improvement in the prognosis for CML patients and a decrease...
2.
Beldzinska-Gadek K, Zarzycka E, Pastuszak K, Borman K, Lewandowski K, Zaucha J, et al.
Leuk Lymphoma
. 2024 May;
65(9):1292-1302.
PMID: 38775354
Acute leukemia (AL) with a lineage switch (LS) is associated with poor prognosis. The predisposing factors of LS are unknown, apart from rearrangements that have been reported to be associated...
3.
Sobieralski P, Bieniaszewska M, Bolkun L, Sacha T, Muzalewska-Wolska M, Homenda W, et al.
Adv Clin Exp Med
. 2024 Apr;
34(1):25-32.
PMID: 38683044
Background: The treatment of patients with polycythemia vera (PV) and essential thrombocythemia (ET) is conducted according to well-defined risk stratification systems. We hypothesized that adherence to the guidelines, namely the...
4.
Kwasnik P, Zaleska J, Link-Lenczowska D, Zawada M, Wysoglad H, Ochrem B, et al.
Cells
. 2024 Apr;
13(8.
PMID: 38667336
Treatment-free remission (TFR) is achieved in approximately half of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors. The mechanisms responsible for TFR maintenance remain elusive. This study aimed...
5.
Prejzner W, Piekos O, Beldzinska K, Sadowska-Klasa A, Zarzycka E, Bieniaszewska M, et al.
Front Oncol
. 2023 Nov;
13:1228481.
PMID: 37941558
Primary refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype myeloid/T-cell acute leukemia have dismal prognoses. New treatment approaches, preferably targeting specific leukemic aberrations to overcome resistance, are...
6.
Madejczyk A, Canzian F, Gora-Tybor J, Campa D, Sacha T, Link-Lenczowska D, et al.
Front Oncol
. 2022 Oct;
12:952640.
PMID: 36212403
Introduction: Functional single-nucleotide polymorphisms (SNPs) in genes regulating cellular uptake, elimination, and metabolism of xenobiotics may potentially influence the outcome of chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine...
7.
Sacha T, Szczepanek E, Dumnicka P, Gora-Tybor J, Niesiobedzka-Krezel J, Prejzner W, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Dec;
22(6):405-415.
PMID: 34933827
Introduction: Tyrosine kinase inhibitors (TKIs) have greatly improved the treatment outcome for most patients with chronic myeloid leukemia (CML). Ponatinib is a new pan-inhibitor of TK active in resistant CML....
8.
Macauda A, Piredda C, Clay-Gilmour A, Sainz J, Buda G, Markiewicz M, et al.
Int J Cancer
. 2021 Mar;
149(2):327-336.
PMID: 33675538
Gene expression profiling can be used for predicting survival in multiple myeloma (MM) and identifying patients who will benefit from particular types of therapy. Some germline single nucleotide polymorphisms (SNPs)...
9.
Pfirrmann M, Clark R, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al.
Leukemia
. 2020 Jul;
34(8):2138-2149.
PMID: 32601376
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our...
10.
Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Stromberg U, et al.
Am J Hematol
. 2019 Aug;
94(11):1236-1243.
PMID: 31456269
Chronic myeloid leukemia (CML) is usually diagnosed in chronic phase, yet there is a small percentage of patients that is diagnosed in accelerated phase or blast crisis. Due to this...